Citations

Clear

10 citation(s) found for "Miller, Jennifer".

Potential Role of Serum Cytokines and Chemokines as Biomarkers of Injury Severity and Functional Outcomes Following Pediatric Traumatic Brain Injury
Swaby, K., Skirvin, Alexander J. , Machado, Natalie Reichert, Bernal, Julia, Fuentes, Ana, Pringle, Charlene , Guthrie, Kourtney, Coto, Jennifer , Dhanashree, Rajderkar, Gober, Joslyn , Perez, Paula Karina, Solano, Juan P. , McCrea, Heather J. , Loor-Torres, Ricardo , Kaufman, Joyce, Alkhachroum, Ayham , O’Phelan, Kristine H., Kobeissy, Firas, Dietrich, W. Dalton, Vaccari, Juan Pablo de Rivero , Pareja, Jennifer C Munoz, Pareja, Jennifer C. Muñoz , Kobeissy, Firas , Swaby, Kathryn , Mateo Chavez, Maria, Fuentes, Ana , Pringle, Charlene P , Dhanashree, Rajderkar , McCrea, Heather J , Kobeissy, Firas , de Rivero Vaccari, Juan Pablo , Munoz Pareja, Jennifer C , Chavez, Maria Mateo , Keane, Robert W. , Wang, Kevin , Dietrich, W. Dalton

Mayo Clinic

Cells | December 22, 2025 | Volume: 15 | Issue: 1 | Pages: 19

10.3390/cells15010019 | PMID 41511302 Get It

Traumatic brain injury (TBI) is one of the leading causes of death and neurological disability worldwide. The search for biomarkers that indicate TBI severity and prognosis with greater accuracy is ongoing. This study aimed to evaluate the significance of several neuroinflammatory cytokines and chemokines, assessing their potential as biomarkers in pediatric TBI (pTBI). This was an exploratory analysis of inflammatory cytokines and chemokines measured in a subset of 26 children aged 0–18 years with TBI and 21 controls. TBI severity was determined by GCS. The functional outcome was measured via the GOS-E score at 6 weeks and 3, 6, 9, and 12 months post-injury. Serum samples were analyzed for ICAM-1, VCAM-1, SAA, CRP, IFN-g, IL-10, IL-12p70, IL-13, IL-1b, IL-2, IL-4, IL-6, IL-8, TNF-a, TNF-b, eotaxin, eotaxin-3, IP-10, MCP-1, MCP-4, MDC, MIP-1a, MIP-1b and TARC. Levels of IL-6, IL-10, IL-13, IL-16, MDC, and GM-CSF were increased, and IFN-γ, IL-5, IL-8, and eotaxin-3 were decreased at enrollment when compared with controls. Elevated IL-6 and IL-10 at enrollment were associated with severe TBI (AUC of 1, p = 0.0002 and p = <0.0001, respectively). IL-6, IL-10, IL-16, and TNF-β at enrollment and IL-5 at 24 h were elevated in children with unfavorable outcomes, with an AUC > 0.8, suggesting biomarker potential. Our data indicate that several cytokines and chemokines measured after TBI may aid in the assessment of pTBI severity and prognosis. IL-6, IL-10, and IL-16 may show potential as biomarkers for pTBI severity and outcomes.
Toward Patient-Centered AI Fact Labels: Leveraging Extrinsic Trust Cues
Yoo, Dong Whi , Stroud, Austin M. , Zhu, Xuan , Barry, Barbara , Miller, Jennifer E , Barry, Barbara

Mayo Clinic

Proceedings of the 2025 ACM Designing Interactive Systems Conference | July 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: 676-690

10.1145/3715336.3735758 | PMID 41019587 Get It

Cultivating Patient-Centered Healthcare Artificial Intelligence Transparency: Considerations for AI Documentation
Stroud, Austin M. , Barry, Barbara , Miller, Jennifer E , Barry, Barbara

Mayo Clinic

The American Journal of Bioethics | February 24, 2025 | Volume: 25 | Issue: 3 | Pages: 129-131

10.1080/15265161.2025.2457775 | PMID 39992835 Get It

Evolving trends in novel sleep tracking and sleep testing technology publications between 2020 and 2022
Schutte-Rodin, Sharon, Ratnasoma, Dulip, Baron, Kelly Glazer , Deak, Maryann C., Jerkins, Evin, Baughn, Julie , Gipson, Kevin S. , Miller, Jennifer N. , Paruthi, Shalini, Shah, Sachin, Bandyopadhyay, Anuja , Holfinger, Steven , Chiang, Ambrose , Gruber, Reut , Shah, Sachin

Mayo Clinic

Journal of Clinical Sleep Medicine | January 10, 2025 | Volume: 21 | Issue: 5 | Pages: 891-905

10.5664/jcsm.11562 | PMID 39789983 Get It

COVID-19 Care Clinic in a Medical Center: Lessons Learned
Tulledge‐Scheitel, Sidna M. , Billings, Thomas A., Homme, Jason H. , Miller, Jennifer , North, Frederick , Sanderson, Rachael L. , Schroeder, Darrell R. , Vaughan, Marvin A., Croghan, Ivana T. , Miller, Jennifer M, Sanderson, Rachael L , Croghan, Ivana T , Schroeder, Darrell , Billings, Thomas A., Fischer, Karen M.

Mayo Clinic

Journal of Primary Care & Community Health | December 7, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211056796 | PMID 34872410 Get It

Objective: The purpose of this report is to describe the elements of a Covid-19 Care Clinic (CCC), patient demographics, and outcomes. Methods: Descriptive statistics were used to describe demographics, clinical characteristics, and outcomes. This report is based on 4934 unique patients seen in the CCC who provided research authorization within a 10-month period of time (April 1, 2020-January 31, 2021). The CCC infection control processes consisted of a rooming process that mitigated SARS-COV-2 transmission, preparing examination rooms, using PPE by staff, in room lab drawing, and escorting services to minimize the time in clinic. Results: Of the 4934 unique patients seen (age range newborn-102 years), 76.8% were tested for COVID-19. Of those tested, 11.8% were positive for SARS-CoV-2. Ninety-two percent of the patients with the reason for the visit documented had COVID-19 type symptoms. Cough, shortness of breath, and chest pain were the most common presenting symptom in those with COVID-19. At the time of the visit in the CCC, 5.8% of the patients were actively contagious. Thirty days after being seen in the CCC, 9.1% of the patients were seen in the emergency department (ED) and 0.2% died. During the 10-month period there were no known occupationally related COVID-19 infections. Conclusion: The COVID-19 Care Clinic provided face-to-face access for all ages with COVID-19 type symptoms. A minority of patients had COVID-19 who were seen in the clinic. The clinic provided an additional venue of care outside of the ED. The infectious control measures employed were highly effective in protecting the staff. Lessons learned allow for decentralization of COVID-19 symptom care to the primary care practices employing the infection control measures.
Evaluating consumer and clinical sleep technologies: an American Academy of Sleep Medicine update
Schutte-Rodin, Sharon, Deak, Maryann C., Khosla, Seema, Goldstein, Cathy , Yurcheshen, Michael , Chiang, Ambrose , Gault, Dominic, Kern, Joseph, O’Hearn, Daniel J. , Ryals, Scott, Verma, Nitun, Kirsch, Douglas B. , Baron, Kelly Glazer , Holfinger, Steven , Miller, Jennifer N. , Patel, Ruchir, Bhargava, Sumit, Ramar, Kannan , Holfinger, Steven J

Mayo Clinic

Journal of Clinical Sleep Medicine | July 27, 2021 | Volume: 17 | Issue: 11 | Pages: 2275-2282

10.5664/jcsm.9580 | PMID 34314344 Get It

Abstract 2360: Central Sleep Apnea with Nocturnal Hypoxia Promotes Increased Circulating Erythropoietin in Heart Failure
Miller, Jennifer , Olson, Lyle J. , Calvin, Andrew D. , Somers, Virend K. , Steensma, David P.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 118 | Issue: suppl_18 | Pages: No page available

10.1161/circ.118.suppl_18.s_709-a Get It

Central sleep apnea (CSA) with nocturnal hypoxia is frequent in heart failure (HF). Hypoxia causes increased circulating erythropoietin (EPO) in healthy normals. EPO promotes increased vasoconstriction and exogenous EPO administration is associated with adverse cardiovascular events. No prior studies have related EPO concentration to apnea or hypoxia due to CSA. EPO is elevated in HF patients with nocturnal hypoxia due to CSA. Ambulatory, non-anemic HF patients (n = 29) with LVEF < 45% and healthy controls (n = 18) underwent polysomnography (PSG). Subjects with obstructive sleep apnea (OSA) were excluded. CSA was defined as apnea-hypopnea index (AHI) ≥ 15. Hypoxia was quantified as the proportion of sleep with arterial oxygen saturation < 90% (T90%). Blood for EPO was drawn post-PSG. Other clinical characteristics were summarized from the medical record. HF subjects and controls were similar age (54 vs 60 y, p = 0.09). CSA was present in 14 HF subjects; 13 were men compared to 8 of 15 without CSA (p = 0.04). HF subjects had 42% higher mean EPO than controls (p < 0.01) despite similar hemoglobin (13.9 vs 14.0 g/dL, p = 0.8). NYHA class III–IV HF subjects had 42% higher mean EPO than class I–II HF subjects (p = 0.05, figure ). EPO concentration was correlated with severity of nocturnal hypoxia by simple linear regression (r = 0.4; p = 0.02). By multivariate analysis, elevated EPO was associated with NYHA class III–IV HF and elevated AHI (p = 0.01 and 0.03, respectively; r = 0.6) after adjusting for age, gender, LVEF, renal function and hemoglobin. Nocturnal hypoxia due to CSA promotes increased endogenous EPO concentration in HF patients.
COVID Care Clinic: A Unique Way for Family Medicine to Care for the Community During the SARS-CoV-2 (COVID-19) Pandemic
Jacobson, Nathan A. , Nagaraju, Darshan, Miller, Jennifer , Bernard, Matthew , Miller, Jennifer M

Mayo Clinic

Journal of Primary Care & Community Health | October 22, 2020 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/2150132720957442 | PMID 33089725 Get It

The COVID-19 pandemic has presented new challenges in how Primary Care clinicians care for community patients. Our organization quickly allocated 1 of our community clinic sites into a dedicated COVID Clinic caring for the COVID positive or any patient with COVID like symptoms to minimize contact with the well patients. A prerequisite for all patients to be seen in the COVID Care Clinic was a virtual visit staffed with Advanced Practice Providers that would further determine if the patient needed to seek emergency medical care or be seen in the COVID Clinic. From March 23, 2020 through May 15, 2020, 852 patients with COVID symptoms were seen in this clinic rather than the emergency department. This article describes a collaborative effort to care for a community during the COVID-19 pandemic. This unique setting allowed us to focus an appropriate level of care to a high risk population in a safe and effective manner in the ongoing effort to flatten the epidemiological curve.
Factors Associated with Treatment and Survival of Early Stage Pancreatic Cancer in the Era of Modern Chemotherapy: An Analysis of the National Cancer Database
Watson, Michael , Miller-Ocuin, Jennifer L., Driedger, Michael R. , Beckman, Michael J., Baker, E. , McKillop, Iain H. , Martinie, John B. , Vrochides, Dionisios V. , Iannitti, David A. , Ocuin, Lee Mayer

Mayo Clinic

Journal of Pancreatic Cancer | September 21, 2020 | Volume: 6 | Issue: 1 | Pages: 85-95

10.1089/pancan.2020.0011 | PMID 32999955 Get It

The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes
Walker, Denise L., Miller, Jennifer, Benson, Linda M., Tomlinson, Andrew J., Naylor, Stephen , Blajeski, April L., LoRusso, Patricia , Ames, Matthew M. , Reid, Joel M.

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 10 | Issue: 4 | Pages: 1471-1480

10.1158/1078-0432.ccr-0557-03 | PMID 14977851 Get It

Abstract Pyrazoloacridine (PZA) is an experimental antitumor agent presently under investigation for treatment of solid tumors on the basis of its unique mechanism of action and selectivity for human solid tumor xenograft in mice. Using capillary electrophoresis coupled with electrospray ionization mass spectrometry, we have identified three oxidative PZA metabolites, 9-desmethyl-PZA, N-demethyl-PZA, and PZA N-oxide. The cytochrome P450 (CYP) isoforms involved in PZA metabolism were characterized by studies with CYP chemical inhibitors, correlation of marker activities for selected CYPs with formation of the metabolites using a human liver panel, and PZA metabolism by cDNA-expressed CYPs. 9-Desmethyl-PZA formation was catalyzed by CYP1A2, whereas N-demethyl-PZA formation was catalyzed by CYP3A4. PZA N-oxide formation was catalyzed by flavin monooxygenase (FMO) rather than CYP, as determined by studies with chemical inhibitors of FMO and metabolism by cDNA-expressed human flavin monooxygenase. After administration of [10b-14C]PZA to mice, six urinary metabolites were detected by high-performance liquid chromatography UV and radiochromatograms including 9-desmethyl-PZA, N-demethyl-PZA, and PZA N-oxide. Trace concentrations of 9-desmethyl-PZA and PZA N-oxide were detected in mouse plasma. PZA N-oxide and N-demethyl-PZA were detected in urine from patients after PZA administration. PZA, 9-desmethyl-PZA, and PZA N-oxide inhibited growth of A375 human melanoma cells. IC50 values were 0.17, 0.11, and 7.0 μm, respectively, for the three molecules.